Merck & Co., Inc. stock (US58933Y1055): Key cancer drug data and dividend profile in focus
Merck & Co., Inc. is gaining attention for its strong oncology data, particularly concerning its blockbuster cancer therapy Keytruda, and its consistent dividend payouts. The article details Merck's business model, emphasizing its focus on R&D, product diversification, and robust financial profile, while also noting the risks associated with its reliance on Keytruda. Key updates on its pipeline and significance for US investors are also highlighted.
TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth
TG Therapeutics has raised its revenue guidance for 2026, primarily due to the strong performance of its multiple sclerosis drug, Briumvi. The company is actively pursuing new autoimmune indications for Briumvi, indicating a strategic focus on expanding its core product's market reach. While this approach concentrates both opportunity and risk, investors are showing confidence, with the stock up 29% in the past three months.
Johnson And Johnson MedTech Moves And Innovation Hub Tie In Shape Outlook
Johnson & Johnson has expanded its MedTech footprint by launching the Shockwave C2 Aero Coronary IVL Catheter and securing naming rights for the New Jersey Innovation Hub. These moves aim to reinforce J&J's role in healthcare technology and support startups. Investors are advised to track these developments, as they diversify J&J's business beyond pharmaceuticals and show positive momentum for the stock, despite a noted risk of high debt.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Bristol Myers Squibb (NYSE: BMY) announced it will present new oncology data at the 2026 ASCO Annual Meeting, showcasing its diverse pipeline with over 60 disclosures and 19 oral presentations. Key highlights include late-breaking Phase 3 results for mezigdomide in multiple myeloma, new data for iza-bren in breast and esophageal cancers, and pumitamig in non-small cell lung cancer. The presentations will also feature advancements in cell therapy, reinforcing the company's commitment to delivering innovative treatments for various cancers.
Lilly’s triple-acting obesity drug hits goal in Phase 3 trial
Eli Lilly's experimental obesity drug, retatrutide, showed significant weight loss in a Phase 3 trial, with some participants losing up to 28% of their body weight over 80 weeks. This triple-acting drug, dubbed a "triple-G," is expected to surpass Lilly's current market leader, Zepbound, and set a new benchmark for competitors like Novo Nordisk. The trial results, which included participants with non-diabetic complications, highlight retatrutide's strong efficacy and acceptable safety profile, potentially expanding Lilly's already substantial obesity franchise.
Tempus AI (TEM) executive logs 13,550-share tax sell-to-cover transaction
Tempus AI (TEM) executive Fukushima Ryan sold 13,550 shares of Class A Common Stock at a weighted average price of $44.07 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations from restricted stock unit vesting, not a discretionary sale. Following the transaction, Ryan directly holds 603,558 shares and indirectly holds 211,047 shares through his spouse.
Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response
Black Diamond Therapeutics (Nasdaq: BDTX) announced positive Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. The drug demonstrated an 86% brain response rate and a 60% overall tumor response rate, along with a median progression-free survival of 15.2 months. These findings support a 150 mg once-daily dose for future pivotal development, and the company plans to discuss its pivotal development plan with the FDA later this year.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Bristol Myers Squibb will present over 60 disclosures and 19 oral presentations at the 2026 ASCO Annual Meeting, showcasing new data from its oncology portfolio and next-generation pipeline. Key highlights include late-breaking Phase 3 results for mezigdomide in multiple myeloma, and presentations on other novel therapies like pumitamig, iza-bren, iberdomide, and golcadomide across various cancer types. The company emphasizes its focus on targeted protein degradation, bispecifics, ADCs, and cell therapy to offer innovative treatment options to cancer patients.
Amgen CFO Change Puts Focus On Debt, Growth And Capital Discipline
Amgen has announced that its long-serving CFO, Peter Griffith, will retire, with Thomas Dittrich appointed as his successor, effective September 1, 2026. This transition is significant for investors, as the new CFO's approach to capital allocation and debt management will be crucial, especially given Amgen's current debt levels and ongoing regulatory scrutiny for certain products. The extended handover period until January 2027 suggests a smooth transition, but investors will be closely watching for shifts in the company's financial discipline and communication regarding growth and spending.
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus (AGEN) shares have dropped 19.4% in the last month following disappointing Q1 2026 results. The company's primary growth driver is its immuno-oncology combination, BOT/BAL, which is progressing through phase III trials and expanding access internationally. Despite promising pipeline advancements, Agenus faces significant competition from larger pharmaceutical companies, leading to a "Hold" rating from Zacks Investment Research.
Merck & Co., Inc. stock (US58933Y1055): cancer franchise drives outlook after latest Keytruda data
Merck & Co., Inc. has highlighted new clinical data for its cancer drug Keytruda and provided updates on its late-stage pipeline, reinforcing growth expectations despite future patent expiries. The company positions itself as a leading oncology and vaccines player, with Keytruda remaining its dominant revenue driver and vaccines contributing stable growth. Merck's strategy involves sustained R&D investment, strategic collaborations, and diversification across therapeutic areas to mitigate competitive and regulatory pressures.
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers Squibb is expanding its focus into neuroscience, particularly in Alzheimer's disease, beyond the traditional amyloid hypothesis. The company is actively pursuing diversified approaches, including targeting tau protein, neuroinflammation, and other mechanisms like EIF2b, while also acknowledging the validated role of amyloid. Despite modest initial sales for its schizophrenia drug Cobenfy, Bristol Myers remains committed to building a psychiatry franchise and leveraging advanced biomarker tools for earlier diagnosis and treatment of neurological disorders.
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Bristol-Myers Squibb (BMY)
Analysts from Wells Fargo and Bank of America Securities have issued bullish ratings for UnitedHealth (UNH) and Bristol-Myers Squibb (BMY), respectively. Wells Fargo maintained a Buy rating for UnitedHealth with a $397.00 price target, while Bank of America Securities reiterated a Buy rating for Bristol-Myers Squibb with a $67.00 price target. Both companies received a Moderate Buy consensus rating from analysts.
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer (PFE)?
Pfizer recently announced strong Phase 2 data for its 25-valent pneumococcal vaccine in infants and secured European approval for HYMPAVZI's expanded use in hemophilia patients. These developments enhance Pfizer's position in complex vaccines and rare hematology, aligning with its strategy to offset patent expirations and pricing pressures through targeted innovation. Investors are encouraged to consider these pipeline successes against ongoing challenges like patent Cliffs and drug price reforms affecting future earnings and dividend stability.
Revolution Medicines Recasts RAS Story With Phase 3 Win And New Firepower
Revolution Medicines has announced groundbreaking overall survival results from its Phase 3 RASolute 302 trial in metastatic pancreatic cancer, alongside a clinical collaboration with Summit Therapeutics and plans to acquire EQRx, Inc. These developments, which include significant capital infusion, aim to solidify Revolution Medicines' position in RAS-targeted oncology and broaden its therapeutic pipeline. The company's stock, NasdaqGS:RVMD, has seen substantial gains, reflecting investor interest in these strategic moves and clinical milestones despite facing high operating expenses and concentration in RAS-targeted oncology.
AstraZeneca plc stock (GB0009895292): Latest catalyst after recent company news
AstraZeneca plc (GB0009895292) remains a key focus for investors, particularly those in the U.S. seeking global pharmaceutical exposure. The company's performance is driven by its strong portfolio in oncology, cardiovascular, respiratory, and rare diseases, with investor attention centered on clinical trial data, regulatory approvals, and pipeline updates. The article emphasizes AstraZeneca's significance as a bellwether for the broader pharma industry and its potential as a defensive investment during economic uncertainty.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN
Silexion Therapeutics Corp (SLXN) shares surged nearly 97% on Wednesday following news of Israel's approval for a Phase 2/3 clinical trial for its pancreatic cancer drug, SIL204, but then dropped in after-hours trading. Despite this positive clinical development, the company faces significant challenges including a widening net loss, dwindling cash reserves, potential stock dilution from warrants, and the need to maintain its Nasdaq listing through a planned 1-for-10 reverse stock split. The article also highlights competitive pressures in the pancreatic cancer drug development space.
Eric Lefkofsky sells TEM (NASDAQ: TEM) Class A shares reported in Form 144
Eric Lefkofsky and affiliated entities GMD and BMD reported sales of Tempus AI, Inc. (NASDAQ: TEM) Class A Common Stock through a Form 144 filing. The filing details multiple dispositions from February 19, 2026, to April 28, 2026, by Eric Lefkofsky, Blue Media, LLC, and Gray Media, LLC, along with related proceeds. The sales include a total of 13,587 shares by Eric Lefkofsky and substantial sales by the affiliated media companies, with the filing also referencing previously granted Restricted Stock Units.
Anthropic signs enterprise AI deal with Bristol Myers Squibb
Bristol Myers Squibb has signed a strategic agreement with Anthropic to deploy its Claude AI across various functions including research, manufacturing, and commercial operations. This deployment aims to enhance drug discovery, automate clinical development processes, and integrate AI into all scientific and commercial aspects with robust governance. The collaboration reflects a broader trend of biopharma companies partnering with AI firms to leverage technology for innovation and operational efficiency.
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
Bristol-Myers Squibb has announced a strategic partnership with Anthropic to integrate AI across its operations, aiming to accelerate drug discovery and development. This collaboration will utilize Anthropic's advanced AI capabilities and Tempus' AI-enabled analytical platform, Lens, to refine drug development strategies, particularly in oncology and neuroscience. The initiative seeks to streamline research, clinical development, and manufacturing procesos and has already seen Bristol-Myers Squibb's shares trading higher.
Bristol Myers deepens AI investment with Anthropic deal
Bristol Myers Squibb is expanding its use of artificial intelligence by partnering with Anthropic to deploy its Claude AI tool across its operations. The drugmaker intends for Claude to accelerate software and AI development, aid in research, development, and manufacturing, and tap into the company's institutional knowledge. This move follows similar AI investments by other major pharmaceutical companies like Merck, Novo Nordisk, Takeda, and Lilly, highlighting a growing industry trend to leverage AI for more efficient drug discovery and development, despite challenges like data quality and AI "hallucinations."
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
Pfizer is focusing on oncology for growth, with oncology
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
Bristol Myers Squibb is partnering with Anthropic to integrate its Claude AI model across its operations, aiming to accelerate drug discovery, development, manufacturing, and medical affairs for over 30,000 employees. The company's stock (BMY) saw a 1.74% rise following the announcement, reflecting investor interest in AI's potential to enhance efficiency in the pharmaceutical sector. Analysts maintain a Moderate Buy rating on BMY, with an average price target suggesting an 8.36% upside.
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
Bristol Myers Squibb (BMS) has announced a strategic agreement with Anthropic to integrate Claude Enterprise across its global operations, from research to commercial functions. This collaboration aims to leverage Anthropic's frontier AI, particularly its agentic capabilities, to accelerate drug discovery, development, and delivery by connecting BMS's institutional knowledge and optimizing workflows. The initiative will empower over 30,000 employees and represents a significant evolution in BMS's AI deployment strategy, moving beyond conversational AI to embed intelligent automation directly into critical processes.
Bristol Myers Squibb announces strategic agreement with Anthropic
Bristol Myers Squibb (BMS) has entered into a strategic agreement with Anthropic to widely deploy Claude, an AI system, across its various functions including research, clinical development, manufacturing, commercial, and corporate. This collaboration aims to integrate agentic AI capabilities into daily workflows, moving beyond simple conversational tools, and empowering over 30,000 employees. The focus is on accelerating engineering with Claude Code, embedding agents into drug development workflows, and connecting Claude to BMS's institutional knowledge to enhance innovation for patients.
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update
AbbVie's latest quarterly results show a continued transition away from its former blockbuster drug Humira, with significant growth from immunology drugs Skyrizi and Rinvoq, as well as contributions from aesthetics and neuroscience segments. While Humira sales decline, the company's diversified portfolio aims to reshape its earnings profile. Investors are watching its performance amidst regulatory developments and competitive pressures in the pharmaceutical industry.
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff
Bristol-Myers Squibb is integrating Anthropic’s Claude AI product for over 30,000 employees to enhance its use of artificial intelligence across research, clinical development, and corporate functions. This partnership highlights Anthropic’s strategic focus on expanding its presence within the life sciences sector. The biopharmaceutical giant aims to accelerate software and AI development with the Claude Code tool.
Banque Cantonale Vaudoise Sells 25,225 Shares of Bristol Myers Squibb Company $BMY
Banque Cantonale Vaudoise reduced its stake in Bristol Myers Squibb (BMY) by 19.7% in Q4, selling 25,225 shares and retaining 102,547 shares valued at $5.53 million. This comes as EVP David V. Elkins also sold 30,000 shares worth approximately $1.85 million. Despite insider selling and institutional adjustments, Bristol Myers Squibb reported better-than-expected Q1 earnings with EPS of $1.58 and revenue of $11.49 billion, and maintains a quarterly dividend of $0.63 per share.
AstraZeneca plc stock (GB0009895292): US drug approvals keep pharma giant in focus
AstraZeneca's stock is in the spotlight due to recent US drug approvals and oncology milestones, reflecting investor interest in its pipeline and market position. The company focuses on innovative therapies, particularly in oncology, cardiovascular, renal, and metabolic diseases, with a strong R&D investment and global commercial presence. Its strategic collaborations and diversified product portfolio are key revenue drivers, positioning it competitively in the global pharmaceutical sector despite regulatory challenges.
Immunic names Michael Bonney as board chair By Investing.com
Immunic, Inc. has appointed Michael W. Bonney as Chair of its Board of Directors, effective May 16. Bonney brings over 30 years of biopharmaceutical industry experience, including significant roles at Biogen Inc., Cubist Pharmaceuticals, and Zeneca Pharmaceuticals. His appointment comes at a crucial time for Immunic, as the company anticipates phase 3 ENSURE trial readouts for vidofludimus calcium in relapsing MS.
How New Aficamten Phase 3 Data and Equity Raise Will Impact Cytokinetics (CYTK) Investors
Cytokinetics (CYTK) recently announced positive Phase 3 data for its cardiac drug aficamten, covering both obstructive and non-obstructive hypertrophic cardiomyopathy. Despite robust Q1 2026 revenue of US$19.36 million, the company reported a net loss of US$206.03 million, necessitating a US$700 million equity raise to fund commercialization and trials. This data and capital infusion bolsters confidence in aficamten's market potential, but investors should remain aware of ongoing dilution risks due to continued losses.
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment
OKYO Pharma has appointed Dr. Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing the company's expertise in ophthalmic programs. Dr. Sacchetti brings extensive experience in neuro-inflammatory corneal diseases, aligning with OKYO Pharma's focus on unmet needs in ophthalmology. Her appointment is timely as OKYO Pharma advances its lead product candidate, Urcosimod, which has received IND and Fast Track designations for neuropathic corneal pain.
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma announced that the FDA raised no objections to their proposed amendments for the HARMONIC™ Phase 2 trial of LP-300. The amendments include focusing enrollment on never-smokers with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a single-arm study design. These changes aim to streamline the regulatory path and enhance the potential for LP-300 in a high-need patient population given its differentiated safety profile and emerging efficacy signals.
Pharma giant considers Houston for $1B manufacturing campus
Bristol Myers Squibb Co. is considering Houston's Generation Park for a new $1 billion multi-modal pharmaceutical manufacturing campus, potentially creating 489 jobs by 2031 with an average annual wage of $96,000. The company, which is also looking at 16 other cities, applied for a 10-year tax abatement agreement in the Sheldon Independent School District, with construction projected to start in 2027 and finish in 2029. This follows Eli Lilly and Co.'s recent selection of Generation Park for its $6.5 billion manufacturing plant.
T-cell Engagers Market to Record US$ 58.04 billion by 2035.
The global T-cell Engagers Market is projected to reach US$ 58.04 billion by 2035, growing at a CAGR of 22.73% from its 2025 valuation of US$ 7.27 billion. Key industry developments include advancements in BiTE platforms, expansion of manufacturing capabilities, and strategic collaborations among major pharmaceutical companies like Amgen, Johnson & Johnson, and Regeneron. The market's growth is driven by increasing adoption, investments, and innovations in oncology immunotherapy and autoimmune disease treatments across various regions.
Biotech veteran Michael Bonney becomes Immunic (NASDAQ: IMUX) chair
Immunic, Inc. has appointed veteran biopharmaceutical executive Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026. Bonney brings over three decades of leadership experience, including his role as CEO of Cubist Pharmaceuticals and significant contributions to the launch of Avonex for multiple sclerosis. His appointment coincides with an increase in the board size and an option grant, as Immunic advances its lead program, vidofludimus calcium, through phase 3 trials.
Resona Asset Management Co. Ltd. Sells 21,761 Shares of Bristol Myers Squibb Company $BMY
Resona Asset Management Co. Ltd. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 3.1% in the fourth quarter, selling 21,761 shares and retaining 669,366 shares valued at approximately $36.1 million. The biopharmaceutical company recently reported strong quarterly results, beating analyst estimates with $1.58 EPS and $11.49 billion in revenue, and declared a quarterly dividend of $0.63. Analysts currently rate the stock as a "Hold" with a consensus price target of $61.31.
Bristol Myers Squibb Houston Plant Raises Questions On Value And Outlook
Bristol-Myers Squibb plans a US$1 billion pharmaceutical manufacturing facility in Houston, creating 500 jobs and expanding its US production. This investment comes as the stock trades at US$57.31, with mixed performance over various periods, and raises questions about its influence on the company's production profile, capital allocation, and future earnings, which are currently forecast to decline. Investors are advised to monitor disclosures on timing, product mix, and operating costs.
Handelsbanken Fonder AB Has $68.50 Million Stake in Bristol Myers Squibb Company $BMY
Handelsbanken Fonder AB significantly increased its stake in Bristol Myers Squibb (NYSE:BMY) by 12.5% in the fourth quarter, bringing its total holding to 1,269,920 shares valued at approximately $68.5 million. The article notes that institutional investors collectively own 76.41% of Bristol Myers Squibb's stock. Despite mixed analyst ratings, the company surpassed quarterly earnings and revenue expectations and offers a quarterly dividend of $0.63 per share, yielding 4.4%.
Novartis stock (CH0012005267): U.S. drug pipeline and recent catalyst watch
Novartis is attracting U.S. investors due to its strong ties to prescription drug demand, regulatory choices, and patent-protected product lifecycles. The company's recent updates on its medicines pipeline and capital returns have put the stock under observation as traders evaluate its pipeline execution, U.S. market exposure, and allocation of capital. For U.S. investors, the critical question is whether Novartis can consistently turn its research capabilities into sustained commercial growth, with current disclosures fueling an active debate on earnings quality and launch execution in the healthcare sector.
Regeneron stock sinks after cancer trial miss prompts selloff
Regeneron Pharmaceuticals shares dropped significantly after its late-stage melanoma drug trial, involving a combination of fianlimab and cemiplimab, failed to meet its primary goal of statistical significance for improving progression-free survival. This setback adds pressure amidst weakening Eylea sales, despite the company's efforts to expand its pipeline through a new partnership with Parabilis Medicines. Analysts expressed concern, with some labeling it a "worst-case scenario" for Regeneron's cancer prospects.
Bristol Myers Squibb eyes $1B drug manufacturing campus in Generation Park
Biopharmaceutical company Bristol Myers Squibb is considering building a new $1 billion, 600,000-square-foot manufacturing facility in McCord Development's Generation Park in Houston. The proposed project would create about 490 new jobs and is seeking a 10-year tax abatement. Construction would begin in 2027 and commercial operations by 2030, adding to the growing life sciences sector in the area.
Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
Bristol Myers Squibb has entered into an exclusive single-target licensing agreement with Lonza to advance an antibody-drug conjugate (ADC) against an undisclosed target. BMS gains access to Lonza's SYNtecan linker-payload platform and will handle the research, development, manufacturing, and commercialization. Lonza will receive upfront payments, potential milestone payments, and royalties on net sales, reinforcing the validation of its TOPO1 inhibitor platform in oncology.
The SaaSpocalypse Discount on Salesforce Stock: What $72 Billion in RPO Actually Means for Investors
Salesforce reported a record fiscal year 2026 with $41.5 billion in revenue, the launch of an $800 million Agentforce AI platform, and a $50 billion share buyback program. Despite a "SaaSpocalypse" narrative dragging down its stock, operational data, including a 169% year-over-year increase in Agentforce ARR, contradicts the idea of AI disruption cannibalizing its core business. Analysts widely view Salesforce stock as undervalued, with a mean target of $267, and TIKR’s model suggests a potential 102% return, forecasting a reacceleration of revenue driven by Agentforce adoption in the second half of fiscal 2027.
Bristol Myers looks at Houston for potential $1B manufacturing plant
Bristol Myers Squibb is considering building a new $1 billion manufacturing facility in Houston, Texas, which could employ nearly 500 people. This potential expansion is part of a broader trend of large pharmaceutical companies investing in U.S. manufacturing, partly influenced by incentive programs and the region's suitability for pharmaceutical production. BMS is evaluating multiple sites in the Central and Eastern U.S. for its domestic manufacturing investment.
Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof.
Bristol-Myers Squibb (BMY) is facing patent cliffs and projected revenue decline, making its pipeline critical for future growth. Following a detailed pipeline defense by Chief Commercial Officer Adam Lenkowsky at a BofA conference, key products like REBLOZYL, BREYANZI, and CAMZYOS are driving current growth. The market's uncertainty about the pipeline's ability to offset patent expirations is reflected in BMY's discounted valuation compared to peers, with significant binary events like Milvexian trial results expected to shape its trajectory.
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda
Regeneron Pharmaceuticals Inc. experienced premarket stock declines and Wall Street downgrades after its phase 3 trial for fianlimab in advanced melanoma failed to meet statistical significance compared to Merck's Keytruda. Although the drug combination showed numerical improvement in progression-free survival, it did not cross the statistical threshold, leading analysts like Citi and BMO to lower their ratings and price targets for the company. This setback follows earlier disappointing phase 2 data for fianlimab in non-small cell lung cancer, diminishing the drug's future commercial prospects.
GeoVax moves higher before the bell as traders watch for Mpox vaccine news
GeoVax Labs Inc. shares saw a pre-market rally on Monday despite financial concerns and a lack of new clinical results following its Q1 update. The increase is attributed to anticipation of news regarding its GEO-MVA Phase 3 immunobridging study for mpox and smallpox. The company faces significant financial hurdles, with its cash balance expected to last only until June 2026, necessitating new capital.
Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Regeneron Pharmaceuticals shares decreased premarket by over 10% after its late-stage clinical trial for a skin cancer medication failed to meet its primary goal. The trial, comparing Regeneron's two-drug combination of Fianlimab and cemiplimab against a Bristol Myers Squibb medication, aimed to slow cancer progression in newly diagnosed melanoma patients but was unsuccessful. This setback follows a year-to-date decline of 9.5% for Regeneron's stock.
Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
Bristol Myers Squibb has entered into an exclusive single-target licensing agreement with Lonza, a CDMO, to advance an Antibody-Drug Conjugate (ADC) for an undisclosed target. BMS will utilize Lonza's SYNtecan linker-payload platform for research, development, manufacturing, and commercialization. Lonza is eligible for upfront payments, potential milestone payments, and royalties on resulting product sales, validating its platform's strength in delivering positive clinical outcomes.
